How Does This Life Sciences Platform Operate?
IQVIA Holdings Inc provides services and technology to the life sciences industry, supporting research and development and related commercial activities. The business combines data-driven capabilities with outsourced services used by healthcare and pharmaceutical customers. Its work spans recurring, long-running client programs alongside more project-based engagements. At roughly USD 28.6 billion in market value, it sits at a scale where execution consistency tends to matter.
Are Margins and Cash Flow Holding Steady?
FundamentalsFor 2025, reported in USD, revenue was USD 16.3 billion, with EBIT of USD 2.2 billion and net income of USD 1.36 billion. Revenue grew 5.9% versus the prior year, alongside a trailing gross margin of 32.99% and an operating margin of 13.22%.
Cash stood at USD 2.0 billion against total debt of USD 3.68 billion. Depreciation and amortization were USD 1.14 billion, while capital spending was USD 75 million. The company’s cash flow proxy—based on EBIT after tax, plus depreciation and amortization, minus capital spending, excluding working-capital changes—was about USD 3.0 billion.
Is The Market Paying Up For Stability?
DCF / MultiplesAt USD 171.50, the shares trade above the central DCF estimate of USD 117.52 and closer to the upper-end value of USD 177.45, with the lower scenario at USD 60.52. On headline multiples, that price corresponds to about 20.67x trailing earnings and 12.23x EV/EBITDA.
Valuation Near Optimistic Range
TakeawayThe valuation sits near the optimistic end of fair value. The case depends on steady revenue growth and resilient margins. Cash generation needs to remain dependable through client cycles. If profitability softens, the current pricing can look stretched. As-is, the setup reads more cautious than compelling.